Free Access
Med Sci (Paris)
Volume 24, Number 3, Mars 2008
Page(s) 306 - 313
Section M/S revues
Published online 15 March 2008
  1. Leclerc C. L’apport des nouvelles technologies en vaccinologie. Med Sci (Paris) 2007; 23 : 386–90. [Google Scholar]
  2. Zagury D, Le Buanec H, Bizzini B, et al. Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev 2003; 14 : 123–37. [Google Scholar]
  3. Belshe RB, Graham BS, Keefer MC, et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID Aids vaccine clinical trials network. JAMA 1994; 272 : 475–80. [Google Scholar]
  4. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother 2007; 30 : 116–22. [Google Scholar]
  5. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356 : 1915–27. [Google Scholar]
  6. Orenstein JM, Preble OT, Kind P, Schulof R. The relationship of serum alpha-interferon and ultrastructural markers in HIV-seropositive individuals. Ultrastruct Pathol 1987; 11 : 673–9. [Google Scholar]
  7. Badou A, Bennasser Y, Moreau M, et al. Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway. J Virol 2000; 74 : 10551–62. [Google Scholar]
  8. Kekow J, Wachsman W, McCutchan JA, et al. Transforming growth factor beta and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc Natl Acad Sci USA 1990; 87 : 8321–5. [Google Scholar]
  9. Gallo RC. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci USA 1999; 96 : 8324–6. [Google Scholar]
  10. Le Buanec H, D’Anna R, Lachgar A, et al. HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes. Biomed Pharmacother 1999; 53 : 424–31. [Google Scholar]
  11. D’Anna R, Le Buanec H, Alessandri G, et al. Selective activation of cervical microvascular endothelial cells by human papillomavirus 16-e7 oncoprotein. J Natl Cancer Inst 2001; 93 : 1843–51. [Google Scholar]
  12. Akagi K, Ikeda Y, Miyazaki M, et al. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer 2000; 83 : 887–91. [Google Scholar]
  13. Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 2005; 435 : 612–9. [Google Scholar]
  14. Le Buanec H, Delavallee L, Bessis N, et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci USA 2006; 103 : 19442–7. [Google Scholar]
  15. Bizzini B, Achour A. « Kinoids »: the basis for anticytokine immunization and their use in HIV infection. Cell Mol Biol 1995; 41 : 351–6. [Google Scholar]
  16. Sabbatini PJ, Kudryashov V, Ragupathi G, et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer 2000; 87 : 79–85. [Google Scholar]
  17. Lamm DL, Dehaven JI, Riggs DR. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol 2000; 37 (suppl 3) : 41–4. [Google Scholar]
  18. Richard M, Grencis RK, Humphreys NE, et al. Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. Proc Natl Acad Sci USA 2000; 97 : 767–72. [Google Scholar]
  19. Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 2006; 36 : 2868–74. [Google Scholar]
  20. Chackerian B, Lenz P, Lowy DR, Schiller JT. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 2002; 169 : 6120–6. [Google Scholar]
  21. Galle P, Hougs L, Barington T, et al. Knocking out IL-6 by vaccination. Eur J Immunol 2004; 34 : 291–300. [Google Scholar]
  22. Spohn G, Guler R, Johansen P, et al. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 2007; 178 : 7450–7. [Google Scholar]
  23. Chensue SW, Terebuh PD, Remick DG, et al. In vivo biologic and immunohistochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxemia. Kinetics, Kupffer cell expression, and glucocorticoid effects. Am J Pathol 1991; 138 : 395–402. [Google Scholar]
  24. Weiner GJ. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol 2000; 68 : 455–63. [Google Scholar]
  25. Gringeri A, Musicco M, Hermans P, et al. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1 infected patients (the EURIS study). J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20 : 358–70. [Google Scholar]
  26. Rad FH, Le Buanec H, Paturance S, et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA 2007; 104 : 2837–42. [Google Scholar]
  27. Le Buanec H, Paturance S, Couillin I, et al. Control of allergic reactions in mice by an active anti-murine IL-4 immunization. Vaccine 2007; 25 : 7206–16. [Google Scholar]
  28. Raaberg L, Nexo E, Jorgensen PE, et al. Fetal effects of epidermal growth factor deficiency induced in rats by autoantibodies against epidermal growth factor. Pediatr Res 1995; 37 : 175–81. [Google Scholar]
  29. Svenson M, Hansen MB, Thomsen AR, et al. Cytokine vaccination: neutralising IL-1alpha autoantibodies induced by immunisation with homologous IL-1alpha. J Immunol Methods 2000; 236 : 1–8. [Google Scholar]
  30. Gonzalez G, Crombet T, Catala M, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998; 9 : 431–5. [Google Scholar]
  31. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344 : 1105–10. [Google Scholar]
  32. Den Broeder A, Van de Putte L, Rau R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002; 29 : 2288–98. [Google Scholar]
  33. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340 : 253–9. [Google Scholar]
  34. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21 : 60–5. [Google Scholar]
  35. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005; 34 : 19–22. [Google Scholar]
  36. Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program 2005; 329–34. [Google Scholar]
  37. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4 : 4 23–36. [Google Scholar]
  38. Silbermann B, Launay O. Prévention des infections à papillomavirus et du zona : nouveaux vaccins. Med Sci (Paris) 2007; 23 : 423–7. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.